KYO-1

A Microchip for Exosome Isolation that can be Impregnated with Imatinib Simultaneously: an In Vitro Analysis

In this study, Monfaredan et al. have created microfluidic devices to separate exosomes from various sources by utilizing magnetic beads that are coupled with CD68. The MTT assay was used for cytotoxicity of imatinib-loaded CD63-Mag caught exosome with chip against KYO-1 cell line. As shown in Fig. 1A to 1C, the free imatinib, imatinib-loaded CD63-Mag caught exosome with chip, and available kits' toxicity on KYO-1 cells are dose dependent. In addition, as cells are treated with the exosome which were extracted by an available kit, the dose was normalized to 100 μmol. It should be mentioned that this compensation could be done by chip, because it can keep the shape and morphology of the caught exosome for longer time. This effective dose was similar to the direct injection of cells with imatinib.

HCA Inhibited Tumor Cell Growth In Vitro

Chronic myelogenous leukemia (CML) is a type of cancer that has been targeted for metabolic regulation via AMPK activation. This study investigates hydroxycitric acid (HCA), a natural bioactive compound from Garcinia gummi-gutta, for its ability to inhibit CML growth by activating AMPK and mTOR pathways.

To test HCA's therapeutic potential on CML, they first examined its effect on CML cell growth in vitro. K562 cells were treated with HCA at concentrations from 1 mM to 100 mM for up to 72 h. Cell viability results showed that HCA inhibited K562 cell proliferation in a concentration-dependent manner, with an IC50 of 11.34 mM (Fig. 2A). Similarly, HCA inhibited the growth of other human CML cell lines (MEG-01, CML-T1, SKH-1, and KYO-1) with IC50 values ranging from 3 to 12 mM (SKH-1, 3.73 mM; CML-T1, 4.67 mM; KYO-1, 8.89 mM; MEG-01, 10.33 mM) (Fig. 2A). However, HCA did not affect the proliferation of normal mouse embryo fibroblasts, even at 100 mM.